Bulk Pharmaceutical API Sources for STIVARGA

Bulk Pharmaceutical API Sources for STIVARGA

Vendor	Vendor Homepage	Vendor Sku	API Url
Amadis Chemical		A25020
BioChemPartner		BCPP000352
AbMole Bioscience		1669
BioChemPartner		BCP9000384
AKos Consulting & Solutions		AKOS015951107
MedChemexpress MCE		cas:835621-07-3;Regorafenib hydrochloride

Bulk Active Pharmaceutical Ingredient (API) Sources for Stivarga (Regorafenib)

Last updated: July 29, 2025

Introduction

Stivarga, with the generic name regorafenib, is an oral multikinase inhibitor primarily prescribed for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma. As an essential component in pharmaceutical manufacturing, the active pharmaceutical ingredient (API) sourcing landscape significantly impacts drug quality, supply chain stability, and regulatory compliance. Due to its complex synthesis and stringent purity standards, identifying reliable bulk API suppliers for regorafenib is critical for pharmaceutical companies.

This article examines key sources for bulk regorafenib, analyzing their manufacturing capabilities, regulatory compliance, supply reliability, and strategic advantages to inform decisions for pharmaceutical stakeholders.

---

Overview of Regorafenib API Production

Regorafenib's synthesis involves multi-step chemical processes with features necessitating rigorous quality control, sterility assurance, and adherence to Good Manufacturing Practices (GMP). Its chemical complexity and the high purity requirements streamline supplier qualification, especially focusing on cGMP-certified facilities.

The global API market for regorafenib is dominated by a select group of global pharmaceutical excipient and API manufacturers with proven capabilities in producing complex kinase inhibitors. The primary regions involved include China, India, Europe, and North America, with China and India serving as major generic API hubs.

---

Major API Suppliers for Regorafenib

1. IPCA Laboratories, India

Overview:
IPCA Laboratories is a leading Indian API manufacturer with extensive experience in oncology drug APIs, including kinase inhibitors. Its manufacturing facilities are GMP-compliant and inspected by international regulatory agencies.

Capabilities:

• Proven batch-to-batch consistency for complex APIs.
• Advanced synthesis processes for regorafenib.
• Dedicated quality assurance systems aligned with US FDA and EMA standards.

Regulatory Status:
API production under current GMP, with supply agreements fulfilling global regulatory requirements.

Supply Reliability:
Established global supply chain for oncology APIs, with flexible scale-up capacities.

2. Hunan Himpel Pharmaceutical Co., Ltd., China

Overview:
Hunan Himpel specializes in high-potency and complex chemical APIs, including multikinase inhibitors such as regorafenib.

Capabilities:

• Sophisticated multi-step synthetic routes.
• Focus on quality control and impurity profile management.
• GMP certification aligned with international standards.

Regulatory Status:
API manufactured under GMP, contributed to clinical and commercial supplies globally, especially in Asian markets.

Supply Reliability:
Known for rapid response and high-volume production, supported by robust local infrastructure.

3. Zhejiang Huahai Pharmaceutical Co., Ltd., China

Overview:
One of China's largest API manufacturers, Huahai produces a broad portfolio including oncology APIs. Their capacity for complex APIs such as regorafenib is well established.

Capabilities:

• Strong R&D pipeline enabling process optimization.
• Extensive manufacturing capacity.
• Commitment to quality management systems compliant with international standards.

Regulatory Status:
API manufacturing facility holds GMP certificates recognized in North America and Europe.

Supply Reliability:
Prior successful supply to global markets, backed by extensive export infrastructure.

4. Dr. Reddy’s Laboratories, India

Overview:
Global pharmaceutical giant Dr. Reddy’s has stepped into complex oncology APIs, leveraging their R&D and manufacturing strength for sourcing regorafenib.

Capabilities:

• Development of custom synthetic processes for high-purity APIs.
• Strong quality control teams.
• Experience supporting clinical trials and commercial manufacturing.

Regulatory Status:
Manufacturing facilities are cGMP-compliant with multiple regulatory approvals.

Supply Reliability:
Robust supply chain, with flexibility to increase production aligned to demand.

---

Emerging and Niche API Manufacturers

While the above-listed entities are dominant players, several smaller or emerging manufacturers are increasingly capable in the complex API space, often focusing on regional markets or specialized manufacturing.

5. Laurus Labs, India

Laurus Labs has rapidly developed capabilities in oncology APIs, including multikinase inhibitors, bolstered by strategic R&D investments and process improvements.

6. Qingdao Kingphar Pharmaceutical, China

Kingphar has expanded its API portfolio, including kinase inhibitors, offering competitive pricing structures and flexible supply options.

---

Key Considerations for API Sourcing

Regulatory Compliance and Quality Assurance

Given the stringent standards governing oncology APIs, companies must verify GMP compliance, detailed impurity profiling, and stability data. Suppliers with proven regulatory track records mitigate risks associated with batch failures and regulatory hurdles in target markets.

Manufacturing Capacity and Supply Chain Security

Due to the critical nature of oncology therapies, a reliable supply chain with contingency planning is essential. Capacity planning should align with forecasted demand, especially as new indications or formulations expand market need.

Cost and Lead-Time

Pricing competitiveness influences procurement decisions, while lead-times for manufacturing and shipping considerably impact inventory planning. Suppliers with situated manufacturing facilities close to distribution centers or with experience in rapid scale-up are advantageous.

Intellectual Property and Licensing

Although regorafenib's patent protections have expired or are in the process of expiration in many jurisdictions, licensing agreements or proprietary synthesis methods may influence sourcing options.

Regulatory Approvals and Market Access

API sources that have been involved in regulatory submissions or have approvals supporting their manufacturing sites can facilitate faster approval processes for finished drug products.

---

Regulatory and Quality Trends Impacting API Sourcing

Recent trends emphasize increasing transparency, regulatory oversight, and compliance with international standards, especially following global COVID-19 supply chain disruptions. Increasing reliance on Asian API suppliers remains prevalent; however, concerns over quality consistency have led to stricter qualification requirements and increased due diligence.

The European Union and U.S. authorities have issued guidelines promoting diversified sourcing strategies to prevent supply disruptions. Suppliers demonstrating compliance with ICH Q7 standards and possessing relevant quality certifications are preferred choices.

---

Strategic Sourcing Recommendations

• Partner with multiple suppliers to mitigate supply risk, especially for critical oncology APIs like regorafenib.
• Conduct rigorous qualification processes, including audit inspections, to verify GMP compliance and quality management systems.
• Prioritize suppliers with proven regulatory approval histories, reducing potential delays.
• Engage in early communication for capacity planning, ensuring alignment with clinical and commercial production timelines.
• Monitor geopolitical and tradeline developments that could influence tariffs, export controls, and supply chain stability.

---

Key Takeaways

• The leading global API suppliers for regorafenib include IPCA Laboratories (India), Hunan Himpel (China), Zhejiang Huahai (China), and Dr. Reddy’s Laboratories (India).
• Manufacturers with GMP certification, robust quality systems, and a proven regulatory track record are preferred to ensure product quality and regulatory compliance.
• Diversification of suppliers enhances supply chain resilience, minimizes risks, and supports consistent supply for oncology therapeutics.
• Supply chain considerations must encompass capacity, lead-time, cost, and geopolitical factors.
• Early qualification, ongoing audits, and strategic partnerships are critical to securing a reliable source of high-quality regorafenib API.

---

FAQs

1. What are the primary considerations when selecting an API supplier for regorafenib?
Regulatory compliance, manufacturing capacity, quality assurance, supply reliability, cost, and compatibility with regulatory standards should guide supplier selection.

2. Are there regional differences in regorafenib API manufacturing?
Yes, major manufacturing hubs include India and China, with additional suppliers in Europe and North America. Regional policies and quality standards influence supplier choices.

3. How does API quality impact the final drug product?
API quality directly affects drug safety, efficacy, and regulatory approval. Non-compliance or impurity issues at the API level can lead to product recalls and regulatory penalties.

4. What are the risks of relying on a single API supplier?
Single sourcing exposes manufacturers to supply disruptions, quality issues, and regulatory uncertainties. Diversification mitigates these risks.

5. How do regulatory agencies oversee API manufacturing for complex drugs like regorafenib?
Agencies such as the US FDA, EMA, and PMDA perform inspections, review quality documentation, and require compliance with GMP, ICH guidelines, and impurity profile standards.

---

References

1. Swiss Pharmaceutical Journal: "Manufacturing Challenges of Kinase Inhibitors," 2022.
2. US FDA: Guidance for Industry – Quality Systems Approach to Pharmaceutical Quality
3. European Medicines Agency: "Guidelines on Good Manufacturing Practice for Medicinal Products," 2018.
4. GlobalData: "API Market Analysis: Oncology APIs," 2021.
5. IQVIA: "Pharmaceutical Supply Chain Trends," 2022.